The Science of Making Money
in Biotech

Fortune
Invest

Andy Acker, PM of the Janus Global Life Sciences Fund, is featured in Fortune’s article on breakthroughs in the lab.
READ NOW

Newly Reopened: A Risk-Conscious Small-Cap Fund — Morningstar (1/22/2015)

Andy Acker, PM of the Janus Global Life Sciences Fund, discusses his views in Fortune's article "The Science of Making Money in Biotech." (3/15/2015)


“The Perkins Global Value fund should provide a nice cushion for investors looking for a relatively conservative option.” –Morningstar (1/9/2015)

Having a fixed income anchor in an investor's portfolio remains important. The Janus Flexible Bond Fund is an all-weather, multi-sector fixed income fund that seeks risk-adjusted returns and capital preservation.
Overall Morningstar Rating™
(as of 02/28/2015), Class T Shares, among 906 Intermediate-Term Bond Funds. View detailed Morningstar ratings.

FIND MY SALES DIRECTOR

Enter your ZIP code to get contact information for the wholesaler in your region.

ENTER ZIP:
SUBMIT   

If you are an RIA: CONTACT RIA GROUP

PORTFOLIO ANALYSIS TOOL

Test and analyze portfolio weaknesses and strengths with our Fund vs. Fund, Portfolio Analysis and Portfolio Comparison tools powered by Morningstar.

UPCOMING CONFERENCE CALLS

Building Meaningful Relationships with CPAs featuring John Evans Jr., Executive Director of Janus Labs & John Kuttin, Barron's top 1200 advisor of 2014, CEO of Kuttin Consulting Group